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CYCLOSPORINE (CsA) is an important immunosuppressive cyclic oligopeptide 
dial is extensively metabolized in humans. 
Itecent reports have suggested .that several 
IIIctabolites of CsA may contnbute to the 
'lPffiunosuppressive activity and/or nephro-
:oxicity observed in patients.'-2 We have also 
observed that metabolites 17,I,and21 (M17, 
MI. and M21)3 have immunosuppressive 
activity on alloreactive T cells.· In light of 
these observations, the accurate quantitation 
ofCsA metabolites in transplant patients may 
add valuable information concerning the 
activity of the administered drug. Preliminary 
reports of trough blood concentrations of M 17 
in kidney and heart transplant patients have 
shown higher concentrations of M 17 than of 
CSA.5,6 Low concentrations of some metabo-
lites and analytical problems7 have previously 
prevented a thorough investigation of blood 
concentra tions of M 17, M I, M 18, and M21 in 
transplant patients. The objectives of our 
study were to develop an accurate method to 
quantitate CsA and its metabolites in blood, 
to measure the concentrations of CsA, MI7, 
MJ, MI8, and M2I in the trough blood 
samples of renal, liver, cardiac, and bone 
marrow transplant patients, and to assess met-
abolic differences among patient populations 
receiving CsA. 
PATIENTS AND METHODS 
Patients 
Blood samples were obtained from both hospitalized 
patients and outpatients who were receiving a stable CsA 
dose for at least seven days. The trough blood samples 
were obtained in the morning immediately prior to the 
next drug dose. Nineteen samples were obtained from 12 
liver transplant patients, 18 samples came from 18 heart 
transplant patients, 22 samples came from 22 kidney 
transplant patients, and 14 samples from eight bone 
marrow transplant patients were collected for the study. 
Biochemical information collected on each patient 
included serum creatinine, bilirubin, and liver enzymes. 
Comparisons were made using Student's t test assuming a 
level of significance of P < .05. 
Instrumentation 
The high-performance liquid chromatography 
(HPLC) system incorporated an automated gradient 
controller, two solvent delivery pumps, a model 712 
sample processor, and a Model 441 absorbance detector 
set at 214 nm (Waters Associates, Milford, MA). The 
column was a Resolve C·18, 15 cm x 3.9 mm, 5·micron 
column (Waters) that was heated to 70°C. An LC-18 
pellicular packing (Supelco, Bellefonte, PAl was used to 
pack the guard column. A Model 3390A reporting inte-
grator (Hewlett-Packard, Avondale, PAl was used to 
measure the retention times and integrate peak areas. 
Materials 
CsA and trace quantities of purified MI7, Ml, M18, 
and M21 were generously supplied by G. Maurer (San, 
doz Incorporated, Basel, Switzerland). Bile-derived M 17, 
MI, MI8, and M21 were isolated and purified from the 
bile of liver transplant patients who were receiving CsA 
therapy.) All organic solvents used in the procedures were 
HPLC grade (J.T. Baker Chemical Company, Philips-
burg, NJ). Water was deionized and purified through a 
Barnstead Nanopure II system (Barnstead, Boston, MA). 
The identification of peaks corresponding to M 17, M I. 
M 18, and M21 was performed by comparison of the peak 
retention times and the mass spectral data of those peaks 
in comparison with purified material. The M8 and MI3 
shown on chromatograms were tentatively identified by 
mass spectral ana lysis. 
Sample Preparation and Quantification 
Two milliliters of whole blood were mixed with 50 III 
of cyclosporine D (CsD, 12.5 Itg/mL) in methanol and 2 
mL distilled water. The mixture was extracted with 14 
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mL of diethyl ether, and the ether layer was removed and 
evaporated under nitrogen to dryness. Following the 
reconstitution of the residue in 2 mL methanol and I mL 
water, the solution was defatted twice with 7 mL n-
hexane per washing. The aqueous methanolic solution 
was re-extracted with 7 mL ether, and the ether was again 
removed and taken to dryness. The final dried extract was 
reconstituted in 100 pL of methanol and 40 ItL were 
injected onto the column. The mobile phase consisted of a 
linear gradient of acetonitrile and water as shown in 
Table I. Standards were spiked with M17, MI, MIS, 
M21, and CsA using blank human blood, were extracted, 
and then analyzed. A least-squares linear regression 
analysis was used to calculate linear equations relating 
peak area ratios of individual metabolites or CsA to CsD 
and drug or metabolite concentrations. The correlation 
observed in each case was at least r - .999. The slopes of 
the standard curves of M17, MI, M18, M21, and CsA 
were 0.00315, 0.00240, 0.00260, 0.00239, and 0.00424, 
respectively. The concentrations of M17, MI, MIS, M21, 
and CsA were measured by the ratio of peak areas (CsA 
or metabolitejCsD) equivalent to the concentration mea-
sured on individual standard curves. The precision of the 
assay was evaluated by determining the percent coeffi-
cient of variation upon analyses of at least nine samples 
for each metabolite. 
RESULTS 
The concentrations of CsA and each of the 
metabolites in the trough blood samples of the 
transplant populations are represented in Fig 
1. Figure 2 represents an HPLC chromato-
gram of the extract of 2 mL blood from a liver 
transplant patient and demonstrates the reso-
lution of metabolite peaks from each other. 
The retention times for a complete metabolite 
profile were 10.S minutes (MS), 16.5 minutes 
(MI3), 24.S minutes (MI7), 26.3 minutes 
Table 1. The linear HPLC Gradient Profile Used in the 
C-18. 5-Mieron Column for CsA Metabolite Separation 
Tome Flow Ratll 
(min) (mL/min) Composition • 
0 1.0 47:53 
33 1.0 57:43 
35 1.0 61:39 
37 1.0 65:35 
39 1.0 66:34 
41 1.0 67:33 
52 1.0 67:33 
55 1.0 73:27 
60 1.0 73:27 
63 1.0 47:53 
• Acetonitrile:water. 
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(MI), 27.9 minutes (MI8), 35.0 minutes 
(M21), 45.8 minutes (CsA), and 49.7 minutes 
(CsD). The run time was 71 minutes with th 
final 20 minutes being required to eliminat: 
extraneous lipophilic materials. This HPLC 
system has been used for the analysis of blood 
urine, and bile, and has shown minimal inter: 
ference by other endogenous materials in 
these samples. The coefficients of variation 
for blood metabolite concentration measure_ 
ment were 1.8% for M17 (n = 10),4.9% for 
MI (n = 10),9.3% for MIS (n = 9),7.6% for 
M2I (n = 9), and 1.S% for CsA (n = 10). 
While considerable variability in metabo-
lite concentrations did exist as shown in Fig I, 
the highest quantities of metabolites were 
observed in the liver and cardiac transplant 
patients. The M 17 concentrations in trough 
blood samples were frequently higher than 
CsA concentrations, as shown in Fig 3. Blood 
from liver, heart, and renal transplant patients 
had a higher M 17 to CsA ratio than did the 
samples from bone marrow transplant 
patients (P < .02). In liver transplant patients 
particularly, the M 17 blood concentration 
was higher than the CsA concentration 
(P < .02). The M 17 concentration was not 
significantly different from the CsA concen-
tration in renal, heart, and bone marrow 
transplant patients. The ratio of MI to M17 
concentration was higher in renal transplant 
patients than in the other transplant popula-
tions (P < .02). Eight of the 22 studies in 
renal transplant patients demonstrated an MI 
level that was 70% or more of the M 17 
concentation. Only one of 14 samples from 
bone marrow transplant patients had detect-
able amounts of M21, but this low concentra-
tion of M21 in the blood of bone marrow 
transplant patients may relate to the intrave-
nous (IV) route of administration of CsA.' 
DISCUSSION 
Cyclosporine metabolites can be measured 
in trough blood samples from all transplant 
patients. The high concentrations of M 17 
demonstrated in this study are particularly 
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Fig 1. Bar graph of the concentrations of each of the metabolites (± SOl in all of the patient groupa studied. 
notable in view of the high level of inhibitory 
activity of M 17 against biopsy-grown Iympho-
cytes.9 The trough concentrations of M 17 in 
renal and heart transplant patients were 
higher than CsA, which is similar to previous 
observationsY We also observed that trough 
M 17 concentrations were an average 174% of 
CsA concentrations in liver transplant 
patients. Figure 3 demonstrates that the pre-
disposition for M I 7 levels to be greater than 
CsA concentrations was not only present in 
liver transplant patients, but was also noted in 
heart and renal transplant patients. The con-
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Fig 2. Chromatogram of an extract of 2 mL blood of 
liver transplant patient showing M8. M13. M17 (988 
ng/mLI. M1 (179 ng/mLI. M18 (120 ng/mLl. M21 (256 
ng/mLI. and CsA (2.068 ng/mLl. 
centrations of M 17 were not related to the 
biochemical measurements of renal or hepatic 
function in these patient groups. While the 
radioimmunoassay (RIA) did provide some 
evidence that metabolite concentrations 
might be high in liver transplant patients, 10 
little additional useful information concerning 
metabolite concentrations can be derived from 
the RIA because of its extreme variability in 
reactivity to CsA metabolites. 11 The contribu-
tion of M 17 to the overall immunosuppressive 
activity of CsA should therefore continue to 
be assessed. 
Metabolite I has in vitro immunosuppres-
sive activity but less than that of Ml7 and 
CSA.12 The high concentrations of M I com-
pared to M 17 in renal transplant patients 
were not significantly related to serum creati-
nine, although out patient population was 
limited. The M I concentrations were 50% to 
60% of CsA concentrations in liver, heart, and 
renal transplant patients. Studies of the syner-
gistic effect of CsA metabolites with CsA may 
demonstrate that these concentrations can 
promote a significant pharmacologic or toxi-
cologic effect. The MI8 and M21 trough 
concentrations in blood were relatively low in 
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Fig 3. The concentrations of M17 and CsA in each of tha patients studied. The line plotted represents a 1:1 
ratio between the concentrations. 
comparison with the M 17, M 1, and CsA 
concentrations, but the chromatographic sep-
aration of M 18 and M21 is essential for 
describing CsA disposition in patients. 
A number of important observations were 
made during the analysis of blood samples 
from this patient population. One new CsA 
metabolite elutes from an HPLC column 
under M I 7 in previous analytical methods 
and yet is in the blood in high concentrations 
in one of the patients included in this series. 
Figure 4 demonstrates the chromatogram of 
this patient with the new metabolite near M 17 
(peak 7) and an additional new CsA metabo-
lite (peak 2). The molecular weights of these 
compounds were determined by fast atom 
bombardment/mass spectrometry. The pro-
tonated molecular ion was 1,237 for peak 2 
and 1,221 for peak 7. 
The ratios of the metabolite to CsA concen-
trations change over the course of treatment 
with CsA. The trough blood concentrations 
during early and late CsA treatment in bone 
marrow transplant patients have shown that 
the M17:CsA ratio increased threefold in 5 
months. The study of the two bone marrow 
transplant patients during early and late peri-
ods had the concentration ratio of M 17:CsA 
increasing from 59% and 73% in the early 
period to 195% and 208%, 5 months later. 
Changes in the metabolite pattern in liver 
transplant patients are complicated due to 
functional changes in the new liver. In one 
liver transplant patient, the M 17:CsA ratio 
increased from 104% while in intensive care to 
194% when stable, with the M 1 :CsA ratio 
increasing from 25% to 79%. The study of 
another liver transplant patient on two consec-
utive days showed a very consistent ratio of 
M 17 and M 1 to CsA. As in the CsA trough 
concentration monitoring, the varying pat-
terns and different quantitative amounts of 
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Fig 4. Chromatogram of 
the blood extract of a liver 
transplant patient depicting 
the measured metabolites and 
twO new CsA metabolites 
(peaks 2 and 71. 
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MI 7. MI. MIS. and M21 in the blood of liver. 
heart. kidney, and bone marrow transplant 
patients within and between groups may be 
affected by liver function, blood sampling 
time, concurrent drug therapy. and the CsA 
dose. 
The HPLC system described for the quanti-
tation of CsA metabolites is precise and pro-
vides excellent resolution between metabo-
lites. The sample preparation procedures used 
provided a satisfactory recovery of metabo-
lites from blood. The peaks for MS, M 13, and 
possibly other known metabolites could also 
be quantitated using this sytem. The column 
life is limited using this system (less than 100 
samples) and is related to the critical separa-
M8 
2 hlI3 
10 
MI7 
20 
TIME (min) 
7 
595 
MI8 
tion of these similar compounds. The proper 
extraction of the specimens for CsA metabo-
lites is critical for the removal of lipophilic 
materials that decrease column life. 
In conclusion, high concentrations of CsA 
metabolites were found in the trough blood 
samples of renal, liver. heart, and bone mar-
row transplant patients. The HPLC resolution 
of these compounds for routine analysis is 
possible but requires meticulous attention to 
sample preparation and column care. Further 
studies of the pharmacologic/toxicologic im-
portance of these metabolites in transplant 
patients is essential for a complete under-
standing of the action of CsA. 
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